• Go to navigation
  • Go to content
AstraZeneca Clinical Trials

Astrazeneca Worldwide

  • AstraZeneca Websites
AstraZeneca US

Main navigation

  • Home
  • Therapy Areas
    • Oncology/Infection
    • Cardiovascular
    • Gastrointestinal
    • Neuroscience
    • Respiratory/Inflammation
  • Drug Products
    • All Drug Products
  • Diseases & Conditions
    • All Diseases and Conditions
  • Glossary
  • Contact Us
  • Disclosure Commitment

You are here

  • Home
  • Therapy Areas
  • Cardiovascular

The following trials provide information to treat various types of cardiovascular diseases, both for ongoing and completed clinical trials.  For more information on this therapy area please click here.

There are a number of ways to help you find trial information.  By using these filters you can find (i) recruiting status, (ii) therapy area, (iii) product and/or (iv) phase of drug development.  You can use one or all filters to identify your specific needs.

When a trial completes the results are reported here no later than one year after completion – this is why you may sometimes find that a Report is unavailable when you are searching through ‘closed’ trials.

  • Expand All
  • Collapse All
  • Pages
  • Previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • Next
  • collapse Dosefinding, TG
  • collapse Evaluation of the efficacy of rosuvastatin in daily practice in untreated high risk patients (CHALLENGE)
  • collapse Crestor RUSH (The efficacy of RosUvaStatin for Korean dyslipidemia patients with Hypertension )
  • collapse Evaluation Study of a Management Strategy for Gastroesophageal Reflux Disease (GERD)
  • collapse Zielerreichung in effektivem Lipidmanagement II (Non-interventional study investigating how effective secondary prevention patients are treated to their LDL-C targets)
  • collapse Zielerreichung in effektivem Lipidmanagement I (Non-interventional study investigating how effective secondary prevention patients are treated to their LDL-C targets)
  • collapse A prospective, non-interventional, observational, multi-center trial to evaluate compliance and efficacy in mono and combination treatment of Candesartan cilexetil(Atancand)/ Candesartan cilexetil 16mg, hydrochlorothiazide 12.5mg(Atancand plus) in hypertension.
  • collapse Candesartan and Candesartan/ Hydrochlorothiazide in the Treatment of Patients With Essential Hypertension and a Concomitant Disease Left Ventricular Hypertrophy
  • collapse Compliance of Patients With Essential Hypertension Treated With Candesartan or Candesartan/Hydrochlorothiazide
  • collapse Pan-European Survey on the Under Treatment of Hypercholesterolemia
  • Pages
  • Previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • Next
  • Expand All
  • Collapse All

Page tools

  • Print
  • Bookmark this page

Legal notices

  • Legal notice
  • Privacy policy
  • © AstraZeneca 2013